• 한국임상수의학회지
• /
• 제34권1호
• /
• pp.18-22
• /
• 2017

The aim of this study was to prove that the hypothesis of half dose (HD) allergen-specific immunotherapy (ASIT) in the treatment of canine atopic dermatitis (CAD) would result in a similar success rate compared to the standard dose (SD) ASIT. Clinical signs were evaluated using a third version of the Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) prior to ASIT (day 0), at the end of induction (day 43), and at three month afterwards (day 90). Of the 18 atopic dogs, 12 dogs (SD group: 6; HD group: 6) had a good - excellent response to the house dust mites-specific immunotherapy. The efficacies of ASIT were 66.6% in both groups. The grades of reduction rate CADESI-03 were not different between two groups. Therefore, half dose protocol of house dust mites-specific immunotherapy is an effective and efficient method to treat CAD.

• Journal of Radiation Protection and Research
• /
• 제26권3호
• /
• pp.291-298
• /
• 2001

The designed release rate of liquid effluents from radwaste treatment system should be calculated and evaluated during normal operation, including anticipated operational occurrence and be assured that the release concentration and off-site dose at unrestricted area do not exceed the limits of regulation. The expected annual release rate and off-site dose for the currently operating nuclear power plants in Korea had been calculated and evaluated using PWR-GALE and LADTAP-II which was based on USNRC Regulatory Guide 1.109. Recently, the MOST Notice 2001-2 related to release concentration and off-site dose at unrestricted area was revised to reflect the concept of ICRP-60. It is necessary for KORI 3&4 to re-calculate the release concentration and off-site dose and to compare these results with the limits of regulation. As the results of assessment, we confirmed that the release concentrations were less than its limits of MOST Notice 2001-2 and the off-site dose at unrestricted area using K-DOSE60 was 3.61E-03 mSv/yr to the age of five for the effective dose, and 4.10E-2 mSv/yr to thyroid of the age of five for the organ equivalent dose. We also confirmed the off-site dose was within the limits of MOST Notice 2001-2. Therefore, the release concentration and off-site dose re-evaluated at unrestricted area in KORI 3&4 were well below the regulation limits of MOST Notice 2001-2.

• 대한방사선기술학회지:방사선기술과학
• /
• 제39권3호
• /
• pp.305-312
• /
• 2016

본 연구에서는 진단용 X선 검사에서 환자에게 피폭되는 두부 및 사지를 다양한 선량 계산법을 통해 실측 선량과 비교 실험하였다. 또한 촬영 장비의 형태, 장비 설정조건, X선의 용량, X선관과 환자와의 거리, X선 후방산란차이 등을 고려한 새로운 계산 방법을 제시하여 피폭선량을 산출하였다. 그 결과 피부입사선량이 기존의 선량 계산법보다 실측과의 오차가 줄어들었으며, 환자가 피폭되는 선량을 쉽게 계산할 수 있었고 의료선량 평가가 이루어지게 되어 방사선 관련 종사자들의 의료 선량 관리가 더욱 수월해지는 계기가 될 것으로 사료된다.

• 방사성폐기물학회지
• /
• 제21권3호
• /
• pp.371-381
• /
• 2023

Evaluating the effectiveness of the radiation protection measures deployed at the Centralized Radioactive Waste Management Facility in Ghana is pivotal to guaranteeing the safety of personnel, public and the environment, thus the need for this study. Radiagem^TM 2000 was used in measuring the dose rate of the facility whilst the personal radiation exposure of the personnel from 2011 to 2022 was measured from the thermoluminescent dosimeter badges using Harshaw 6600 Plus Automated TLD Reader. The decay store containing scrap metals from dismantled disused sealed radioactive sources (DSRS), and low-level wastes measured the highest dose rate of 1.06 ± 0.92 µSv·h^-1. The range of the mean annual average personnel dose equivalent is 0.41-2.07 mSv. The annual effective doses are below the ICRP limit of 20 mSv. From the multivariate principal component analysis biplot, all the personal dose equivalent formed a cluster, and the cluster is mostly influenced by the radiological data from the outer wall surface of the facility where no DSRS are stored. The personal dose equivalents are not primarily due to the radiation exposures of staff during operations with DSRS at the facility but can be attributed to environmental radiation, thus the current radiation protection measures at the Facility can be deemed as effective.

• Radiation Oncology Journal
• /
• 제14권1호
• /
• pp.41-52
• /
• 1996

목적 : 외부 방사선 치료(External Radiation Therapy) 및 Gamma-med (Iridium-192) 고선량 강내 방사선 치료를 받은 자궁 경부암 FIGO stage IIB 환자에서 직장 합병증 발생률 및 이와 관계있는 인자를 후향적으로 분석해 보았다. 대상 및 방법 : 1989년 11월부터 1992년 12월까지 연세암센터 치료방사선과에서 근치적 목적의 외부 및 강내 방사선치료를 받은 FIGO 병기 IIB 자궁경부암 환자 88명을 대상으로 방사선치료후 발생한 직장 합병증 및 이와 연관된 인자들을 분석하여 보았다. 환자들의 연령은 29-83세로 평균치, 중앙치 모두 57세였고 병리조직 분류상 편평상피세포암이 84예 선암이 4예였다. 방사선치료는 외부방사선을 골반 부위에 5-6주 동안 4500-5400cGy 치료하였으며 환자별로 중간 차폐를 시행하였고 고선량 Gamma-med ICR은 A점에 1회당 500cGy씩 1주 2회로 총 3000cGy 조사하였다. 외부 방사선치료시 중앙 차폐까지의 외부 조사량, ICR rectal dose(r) 및 total rectal dose(R), ICRU 38에 따른 ICR rectal dose(Dr)와 total Dr dose(OR), ICR reference volume, TDF, BED(Biologically Effective Dose)를 계산하고 분석해 합병증과의 연관성을 찾아보았다. 대상 환자 88명중 87명($98.9\%$)에서 최저 24개월 이상 추적 관찰이 가능하였으며 중앙치는 40개월(20-66개월)이었다. 결과 : 직장 합병증은 27예에서 발생하였는데($30.7\%$) grade 1이 12예($13.6\%$), 2가 12예($13.6\%$), 3이 3($3.4\%$)예였고 합병증이 발생하는 시기는 망사선치료후 4-43개월(중앙치 16개월, 평균 17.3개월)이었다. 직장 합병증이 발생하지 않은 환자군의 total rectal dose(R)는 $6772.67{\pm}884.02$로 grade 2-3 합병증이 발생한 15명의 R=$7163.0{\pm}838.49$와 유의한 차이를 보였으며 total Dr dose (DR)도 두 군간에 차이를 보였다 또 grade 2-3인 직장 합병증 발생률은 중앙 차폐시 까지의 외부 방사선량과 관계가 있었는데 36Gy이하에서는 $10\%$, 36-40Gy는 $21.4\%$, 40Gy 이상에서는 $29.3\%$의 직장 합병증이 발생하여 중앙 차폐까지 조사된 외부 방사선량이 증가할수록 직장 합병증이 증가함을 알 수 있었다. 직장에 조사된 총직장 조사량(R)에 따라 grade 2-3 합병증 발생률이 증가하였는데 65Gy 이하에서는 $10.5\%$, 65-75Gy는 $17.2\%$, 75Gy이상 조사된 환자군에서는 $28.5\%$로 조사량이 증가할수록 직장 합병증이 증가하는 알상이었으며 ICRU 38 에 따른 total rectal dose (DR)에 대해서도 비슷한 양상이었다. ICR rectal dose(r, Dr)만 따로 분석해 보았는데 방사선량과 직장 합병증간에는 차이가 없었다. 그 외의 인자로 분석한 TDF 와 BED도 grade 2-3의 경우에는 그 값이 증가할수록 증가하는 양상을 보였으나 통계적인 유의성은 없었고 Gamma Dot 에서 계산되는 ICR reference volume도 분석해 보았으나 합병증파의 연관성을 발견할 수 없었다. 결론 : 병기 IIB 자궁경부암 환자에서 외부 방사선치료 및 고선량 강내 방사선치료후 직장 합병증 발생률은 $30.7\%$(grade 2-3: 15예 $17\%$)였다. 직장 합병증 발생에 영향을 미치는 중요한 인자는 직장에 조사된 전골반 방사선량(중앙 차폐까지의 방사선량) 및 고선량 강내 방사선 치료와 합한 총직장 방사선량(r, Dr)으로 나타났으며 이들이 증가할수록 합병증 발생률이 증가하였다.

• Journal of Radiation Protection and Research
• /
• 제33권4호
• /
• pp.151-160
• /
• 2008

국내 원전에서는 과거에 불균일 방사선장이 형성되는 고피폭 방사선작업에 2개의 복수선량계(TLD)를 머리와 기슴에 패용하였으며, 이들 선량계 판독값 중에서 최대값을 유효선량으로 평가함으로써 일정 부분이 과대평가되고 있는 것으로 나타났다. 따라서 이러한 문제점을 개선하고자 국제적인 기관에서 제시된 복수선량계 알고리즘을 대상으로 적절한 알고리즘을 선정하기 위한 현장적용 시험을 실시하였다. 여기에는 캐나다 원전사업자(OPG), 미국표준기술협회(ANSI HPS N13.41), NCRP(55/50), NCRP(70/30), EPRI (NRC), Lakshmanan, Kim(Texas A&M University) 알고리즘 등을 대상으로 하였고, 국내 원전의 계획예방정비기간동안 고피폭이 예상되는 방사선작업을 대상으로 작업종사자에게 3개의 복수선량계를 가슴, 머리, 등에 동시에 패용하였고 판독하였다. 이 시험 결과에 따르면 Lakshmanan 알고리즘을 제외하고 유효선량 평가에서 모든 복수선량계 알고리즘이 거의 유사한 경향을 보이는 것으로 나타났다. 한편 현장적용시험 결과와 이들 알고리즘의 기술적 배경과 방사선작업과정에서의 편의성 등을 종합적으로 고려하여 NCRP(55/50) 알고리즘을 최종적으로 선정하였다. 또한 복수선량계 지급조건은 INPO와 ANSI의 지침을 검토하여 빙사선량율이 1 mSv/hr 이상이면서 인체 특정부위 간의 선량율이 30% 이상차이가 나고 단일 작업에서 2mSv 이상피폭을 받을 것으로 예상될 때 지급하는 것으로 결정하였다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권16호
• /
• pp.7167-7170
• /
• 2015

Background: Although 3D image based brachytherapy is currently the standard of treatment in cervical cancer, most of the centres in developing countries still practice orthogonal intracavitary brachytherapy due to financial constraints. The quest for optimum dose and fractionation schedule in high dose rate (HDR) intracavitary brachytherapy (ICBT) is still ongoing. While the American Brachytherapy Society recommends four to eight fractions of each less than 7.5 Gy, there are some studies demonstrating similar efficacy and comparable toxicity with higher doses per fraction. Objective: To assess the treatment efficacy and late complications of HDR ICBT with 9 Gy per fraction in two fractions. Materials and Methods: This is a prospective institutional study in Southern India carried on from $1^{st}$ June 2012 to $31^{st}$ July 2014. In this period, 76 patients of cervical cancer satisfying our inclusion criteria were treated with concurrent chemo-radiation following ICBT with 9 Gy per fraction in two fractions, five to seven days apart. Results: The median follow-up period in the study was 24 months (range 10.6 - 31.2 months). The 2 year actuarial local control rate, disease-free survival and overall survival were 88.1%, 84.2% and 81.8% respectively. Although 38.2% patients suffered from late toxicity, only 3 patients had grade III late toxicity. Conclusions: In our experience, HDR brachytherapy with 9 Gy per fraction in two fractions is an effective dose fractionation for the treatment of cervical cancer with acceptable toxicity.

• 공업화학
• /
• 제7권5호
• /
• pp.938-945
• /
• 1996

Co-60 조사하에서 동시조사법으로 폴리프로필렌 부직포에 스틸렌을 그라프트 중합반응시키면서 조사량, 조사선량률, 용매효과, 산 및 다관능성 단량체의 첨가효과에 대하여 고찰하였다. 같은 조사량의 경우 조사선량률이 낮을수록 그라프트율은 증가하였다. 초기의 그라프트 반응속도는 조사선량의 0.56차수에 비례하였다. 산을 그라프트용액에 첨가하면 전 농도 범위에서 그라프트율이 향상되었으며, 또한 다관능성 단량체를 첨가하여도 그라프트율이 증가하였다. 2개의 비닐기를 가진 DVB에 비하여 3개의 비닐기를 가진 TMPTA를 첨가하면 더 높은 그라프트율을 나타냈다. 한편 산과 다관능성 단량체를 동시에 첨가하면 별개로 첨가한 것보다 훨씬 높은 그라프트 촉진 효과를 나타냈다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권1호
• /
• pp.125-129
• /
• 2016

Background: Patients with differentiated thyroid cancers (DTC) who receive radioactive iodine-131 (RAI) are released from isolation when their dose rate is below the regulatory requirements. The purpose of this study was establish predicting factors for early release from the isolation facility after RAI administration in patients with DTC. Materials and Methods: This was a prospective study which included 96 (58 females and 38 males) patients with DTC who had received RAI from April 2013 till August 2015. The study was duly approved by the ethical committee of the institute. Patients who had complete information of primary tumor size (PTS), serum TSH, stimulated thyroglobulin level [sTg] with antibodies (IU/ml) at the time of RAI treatment were included. All had a normal serum creatinine level. To attain lower effective half-life good hydration and administration of soft laxative were ensured. Dose rate was measured (immediately, 24 h and 36 h) at 1 meter distance from anterior mid trunk and a dose rate <$50{\mu}Sv/h$ was considered as the releasing criterion. At 24 h 50 patients were released while the remaining 46 patients were released at 36 h. A post-ablative whole body scan (PA-WBIS) was performed 5-8 days after RAI ablation in all patients. Results: Patients released after 24 h were significantly younger, had smaller lesions with higher proportion of papillary cancer, lower sTg, lower sTg/TSH ratio and had received a lower dose of RAI as comapred to those who were discharged after 36 h. Serum TSH and gender were not found to have any significant correlation between two cohorts. ROC and multivariate analysis have shown age ${\leq}37years$, PTS ${\leq}3.8cm$, $RAI{\leq}150mCi$, $sTg{\leq}145ng/ml$ and $sTg/TSH{\leq}1.085$ as strong indepedent predictors for early release. Conclusions: We conclude that younger age (${\leq}37years$), smaller tumor size (${\leq}3.8cm$), lower RAI dose (${\leq}150mCi$), lower sTg (${\leq}145ng/ml$) and a lower sTg/TSH ratio (${\leq}1.085$) are significant independent predictors for release at 24 h after RAI treatment in DTC patients. Effective utilization of these factors could help the treating physicians to use limited number of internment facilities with higher throughput, lower cost and lower psychological stress to patients.

• 대한수의학회지
• /
• 제33권1호
• /
• pp.137-143
• /
• 1993

This study was carried out to completelycure the experimental bovine theileriasis with small unilamella vesicle liposome incorporated buparvaquone which was effective both to schizonts in lymphocyte of lymph nodes and piroplasmic stage in erythrocytes. Small unilamella vesicle liposome incorporated buparvaquone was prepared by French pressure cell method using egg phosphatidylcholine. The diameter of the vesicles was ranged from 5 to 220 nm, but the most vesicles were ranged from 10 to 50 nm in diameter. The incorporation rate for buparvaquone was 100%. Parasitaemia of the 10 calves inoculated with $5{\times}10^8$ erythrocytes infected with Theileria sergenti were first detected from on day 16 to day 23 after inoculation. In calves treated with a dose rate 2.5 mg/kg BW of free buparvaquone, a gradual decrease in piroplasmic parasitaemia was observed following treatment to day 5. However parasitaemia levels returned to near pretreatment values after approximately 60 days. In calves treated with a dose rate 5.0mg/kg BW of free buparvaquone, parasitaemia were disappeared on day 3 after treatment, but there was a mild recrudescence of infection on day 28 after treatment. In calves treated intraavenously with a dose rate 2.5 mg/kg BW of buparvaquone incorporated in liposome, the calves were all cured on day 2 or day 3 after treatment. In calves treated subcutaneously and intraperiotoneally with a dose rate 2.5 mg/kg BW of buparvaquone incorporated in liposome, parasitaemia were disappeared on day 3 or day 4 after treatment, but there was a mild recrudescence of infection on day 40 or day 45 after treatment.